Non Hodgkin Lymphoma (NHL) Market Outlook Highlights The Next Major Growth Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Non Hodgkin Lymphoma (NHL) Market Growth Potential: How Will Market Size Change Through 2030?
The non-Hodgkin lymphoma (NHL) market has experienced substantial expansion over recent years. From $10.86 billion in 2025, it is expected to reach $11.73 billion by 2026, progressing at a compound annual growth rate (CAGR) of 8.0%. This historical growth is driven by a global increase in NHL incidence rates, improved chemotherapy treatments, higher healthcare spending, enhanced awareness of lymphatic cancers, and the expansion of oncology hospital facilities.
The non-Hodgkin lymphoma (NHL) market is anticipated to experience substantial expansion in the coming years, with projections indicating it will reach $16.44 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.8%. This forecasted growth is driven by several factors, including an expanding pipeline of targeted therapies, an uptick in approvals for biologics, a greater embrace of personalized medicine, improved access in emerging markets, and an increase in stem cell transplant procedures. Key trends shaping this period encompass the rising adoption of immunotherapy and targeted therapies, a greater utilization of combination treatment regimens, a heightened emphasis on early and precise diagnosis, the broadening of personalized treatment approaches, and a transition toward outpatient and home-based care delivery models.
Download A Free Sample Report For Comprehensive Market Insights:
Non Hodgkin Lymphoma (NHL) Market Growth Drivers And Industry Catalysts
Growing cases of non-Hodgkin lymphoma are set to drive expansion in the market for this condition moving forward. This type of cancer originates in the lymphatic system, a crucial component of the immune system. Its prevalence indicates how many individuals within a given population are currently diagnosed or living with this disease at a particular point in time. Treatments for non-Hodgkin lymphoma aim to improve outcomes for affected patients by targeting and controlling cancerous cells. As an example, data from the American Cancer Society, a cancer-focused health organization based in the US, revealed in January 2023 that non-Hodgkin lymphoma constitutes 4% of all cancers, with an estimated 80,550 Americans expected to be impacted in 2023—44,880 males and 35,670 females. The organization also projects that approximately 20,180 individuals will succumb to the disease in 2023. Consequently, the widespread occurrence of non-Hodgkin lymphoma is fueling growth in this specific market.
Non Hodgkin Lymphoma (NHL) Market Categorization By Product Type And Application
The non hodgkin lymphoma (nhl) market covered in this report is segmented –
1) By Type: B-Cell Lymphoma, T-Cell Lymphoma
2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)
Non Hodgkin Lymphoma (NHL) Market Trends Influencing Long-Term Demand
Major pharmaceutical players in the non-Hodgkin lymphoma sector are intensifying their efforts to develop advanced immunotherapies, including Epcoritamab-bysp (EPKINLY), as a strategy to secure market dominance. This investigational subcutaneous treatment is specifically engineered to target CD20-positive B-cell malignancies, and it has demonstrated notable efficacy in clinical studies, particularly for patients dealing with relapsed or refractory B-cell non-Hodgkin lymphoma. A key development occurred in November 2023, when AbbVie Inc., a U.S.-based pharmaceutical firm, secured a breakthrough therapy designation from the U.S. Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This regulatory nod applies to adults suffering from relapsed or refractory follicular lymphoma who have undergone at least two prior treatment regimens. Furthermore, the European Medicines Agency has accepted a Type II application submission for epcoritamab (TEPKINLY) targeting the same patient population. These milestones are backed by findings from the Phase 1/2 EPCORE NHL-1 trial, which examined the safety and early effectiveness of subcutaneous epcoritamab in a cohort of 128 adult patients with relapsed, progressive, or refractory CD20-positive mature B-cell non-Hodgkin lymphoma, including follicular lymphoma.
Non Hodgkin Lymphoma (NHL) Market Company Landscape And Strategic Competition
Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.
Access The Complete Non Hodgkin Lymphoma (NHL) Market Report:
Non Hodgkin Lymphoma (NHL) Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
